The Alzheimer’s disease space continues to buzz with news – advancements in the science and understanding of the disease, availability of new treatment options, and a newfound sense of hope for the Alzheimer’s community. In a recent interview with PharmaVoice, Prothena CEO Gene Kinney shares, “Science is an iterative process, and for a disease as insidious as Alzheimer’s is for society, it really does take a village — it takes every part of the scientific community to make meaningful progress in this space.”
Prothena is proud to be part of that innovation. At the Alzheimer’s Association International Conference® 2023 (AAIC) in July in Amsterdam, Netherlands, Prothena unveiled data on three investigational Alzheimer’s disease product candidates, showcasing the promise of our pipeline and commitment to transform the care for people living with Alzheimer’s disease. Data on two next-generation antibodies with best-in-class potential, PRX012 and PRX005, and our vaccine, PRX123, further validates ongoing research and underscores the evolution of new treatment pathways to confront this devastating disease. You can read more about our poster presentations here.
For more than a decade, our goal has been to deliver better outcomes for patients. As noted in a recent story in Barron’s, PRX012 is “more potent than other anti-amyloid drugs, and it can be dosed by injection instead of a hospital infusion.” Gene also notes in PharmaVoice that, “PRX123 is relatively unique [because] it simultaneously targets both the amyloid beta protein, which may be an early cause of the disease, but also the tau protein, which becomes a critical component of the disease in progressing to cognitive and functional deficits.”
As always, it is inspiring to immerse ourselves in the latest science, connect with likeminded experts, and share our contributions to the field. We engaged in many insightful discussions and continue to be fueled by our determination to deliver patient-centric solutions as we look to better the care of Alzheimer’s disease patients.